RU2017111848A - Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи - Google Patents
Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи Download PDFInfo
- Publication number
- RU2017111848A RU2017111848A RU2017111848A RU2017111848A RU2017111848A RU 2017111848 A RU2017111848 A RU 2017111848A RU 2017111848 A RU2017111848 A RU 2017111848A RU 2017111848 A RU2017111848 A RU 2017111848A RU 2017111848 A RU2017111848 A RU 2017111848A
- Authority
- RU
- Russia
- Prior art keywords
- prevention
- treatment
- urinary incontinence
- salt
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (10)
1. Терапевтическое средство для профилактики и/или лечения недержания мочи, содержащее:
1-[2-({[транс-3-фтор-1-(3-фторпиридин-2-ил)циклобутил]метил}амино)пиримидин-5-ил]-1Н-пиррол-3-карбоксамид или его соль.
2. Терапевтическое средство для профилактики и/или лечения недержания мочи по п. 1, отличающееся тем, что недержание мочи представляет собой стрессовое недержание мочи.
3. Терапевтическое средство для профилактики и/или лечения недержания мочи по п. 1, отличающееся тем, что недержание мочи представляет собой смешанное недержание мочи.
4. 1-[2-({[транс-3-фтор-1-(3-фторпиридин-2-ил)циклобутил]метил}амино)пиримидин-5-ил]-1Н-пиррол-3-карбоксамид или его соль для профилактики и/или лечения недержания мочи.
5. Соединение или его соль по п. 4 для профилактики и/или лечения стрессового недержания мочи.
6. Соединение или его соль по п. 4 для профилактики и/или лечения смешанного недержания мочи.
7. Способ профилактики и/или лечения недержания мочи, включающий в себя введение эффективной дозы 1-[2-({[транс-3-фтор-1-(3-фторпиридин-2-ил)циклобутил]метил}амино)пиримидин-5-ил]-1Н-пиррол-3-карбоксамида или его соли пациенту.
8. Способ профилактики и/или лечения стрессового недержания мочи по п. 7, отличающийся тем, что включает в себя введение эффективной дозы соединения или его соли пациенту.
9. Способ профилактики и/или лечения смешанного недержания мочи по п. 7, отличающийся тем, что включает в себя введение эффективной дозы соединения или его соли пациенту.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014183434 | 2014-09-09 | ||
| JP2014-183434 | 2014-09-09 | ||
| PCT/JP2015/075567 WO2016039367A1 (ja) | 2014-09-09 | 2015-09-09 | 尿失禁予防用及び／又は治療用新規医薬組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| RU2017111848A true RU2017111848A (ru) | 2018-10-08 |
| RU2017111848A3 RU2017111848A3 (ru) | 2019-07-17 |
| RU2738886C2 RU2738886C2 (ru) | 2020-12-18 |
| RU2738886C9 RU2738886C9 (ru) | 2021-12-06 |
Family
ID=55459111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017111848A RU2738886C9 (ru) | 2014-09-09 | 2015-09-09 | Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9987279B2 (ru) |
| EP (1) | EP3192512B1 (ru) |
| JP (1) | JP6573618B2 (ru) |
| KR (1) | KR102460731B1 (ru) |
| CN (1) | CN106687115B (ru) |
| AU (1) | AU2015313221B2 (ru) |
| BR (1) | BR112017004505A2 (ru) |
| CA (1) | CA2957804C (ru) |
| ES (1) | ES2750751T3 (ru) |
| IL (1) | IL250919B (ru) |
| MX (1) | MX2017002853A (ru) |
| PH (1) | PH12017500436A1 (ru) |
| PL (1) | PL3192512T3 (ru) |
| PT (1) | PT3192512T (ru) |
| RU (1) | RU2738886C9 (ru) |
| SG (1) | SG11201701019UA (ru) |
| WO (1) | WO2016039367A1 (ru) |
| ZA (1) | ZA201701671B (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| MD3413892T2 (ro) | 2016-02-12 | 2022-06-30 | Cytokinetics Inc | Derivați de tetrahidroizochinolină |
| WO2019133605A1 (en) | 2017-12-26 | 2019-07-04 | Astellas Pharma Inc. | Process for the preparation of an amino-pyrimidine and intermediates thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343282B1 (en) | 2004-03-05 | 2015-07-22 | F. Hoffmann-La Roche AG | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
| US20080009538A1 (en) * | 2005-03-21 | 2008-01-10 | Phil Skolnick | Methods and compositions for the treatment of urinary incontinence |
| JP2007176933A (ja) * | 2005-11-29 | 2007-07-12 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JP2007290970A (ja) * | 2006-04-21 | 2007-11-08 | Astellas Pharma Inc | 腹圧性及び混合型尿失禁治療剤 |
| CA2672591A1 (en) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Treating agent of uropathy |
| DK2216021T3 (da) * | 2007-11-02 | 2012-11-05 | Astellas Pharma Inc | Farmaceutisk sammensætning til behandling af overaktiv blære |
| JP5553547B2 (ja) | 2009-07-14 | 2014-07-16 | 俊一 梶岡 | トロポニン含有医薬組成物 |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| CN104379597A (zh) * | 2012-04-02 | 2015-02-25 | 赛特凯恩蒂克公司 | 改善膈肌功能的方法 |
| CA2869675C (en) | 2012-04-11 | 2022-06-14 | Cytokinetics, Inc. | Methods for improving resistance to skeletal muscle fatigue |
-
2015
- 2015-09-09 KR KR1020177009425A patent/KR102460731B1/ko active IP Right Grant
- 2015-09-09 MX MX2017002853A patent/MX2017002853A/es active IP Right Grant
- 2015-09-09 PL PL15839636T patent/PL3192512T3/pl unknown
- 2015-09-09 CN CN201580048573.4A patent/CN106687115B/zh active Active
- 2015-09-09 WO PCT/JP2015/075567 patent/WO2016039367A1/ja active Application Filing
- 2015-09-09 ES ES15839636T patent/ES2750751T3/es active Active
- 2015-09-09 CA CA2957804A patent/CA2957804C/en active Active
- 2015-09-09 SG SG11201701019UA patent/SG11201701019UA/en unknown
- 2015-09-09 US US15/509,394 patent/US9987279B2/en active Active
- 2015-09-09 BR BR112017004505-2A patent/BR112017004505A2/pt not_active Application Discontinuation
- 2015-09-09 EP EP15839636.6A patent/EP3192512B1/en active Active
- 2015-09-09 JP JP2016547468A patent/JP6573618B2/ja active Active
- 2015-09-09 AU AU2015313221A patent/AU2015313221B2/en active Active
- 2015-09-09 PT PT158396366T patent/PT3192512T/pt unknown
- 2015-09-09 RU RU2017111848A patent/RU2738886C9/ru active
-
2017
- 2017-03-02 IL IL25091917A patent/IL250919B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01671A patent/ZA201701671B/en unknown
- 2017-03-08 PH PH12017500436A patent/PH12017500436A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015313221A1 (en) | 2017-03-09 |
| JP6573618B2 (ja) | 2019-09-11 |
| RU2738886C9 (ru) | 2021-12-06 |
| KR20170045353A (ko) | 2017-04-26 |
| PL3192512T3 (pl) | 2020-03-31 |
| CA2957804A1 (en) | 2016-03-17 |
| CN106687115A (zh) | 2017-05-17 |
| SG11201701019UA (en) | 2017-03-30 |
| RU2017111848A3 (ru) | 2019-07-17 |
| US20170273979A1 (en) | 2017-09-28 |
| RU2738886C2 (ru) | 2020-12-18 |
| US9987279B2 (en) | 2018-06-05 |
| CN106687115B (zh) | 2019-07-19 |
| PT3192512T (pt) | 2019-10-29 |
| CA2957804C (en) | 2023-04-04 |
| IL250919A0 (en) | 2017-04-30 |
| ES2750751T3 (es) | 2020-03-27 |
| EP3192512A1 (en) | 2017-07-19 |
| BR112017004505A2 (pt) | 2018-01-23 |
| AU2015313221B2 (en) | 2019-11-21 |
| ZA201701671B (en) | 2019-06-26 |
| EP3192512A4 (en) | 2018-02-07 |
| IL250919B (en) | 2019-10-31 |
| WO2016039367A1 (ja) | 2016-03-17 |
| JPWO2016039367A1 (ja) | 2017-06-15 |
| MX2017002853A (es) | 2018-01-12 |
| EP3192512B1 (en) | 2019-08-14 |
| KR102460731B1 (ko) | 2022-10-28 |
| PH12017500436A1 (en) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500265A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| RS54707B1 (en) | TREATMENT OF CROWN LAKVINIMOD DISEASE | |
| RU2017111848A (ru) | Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи | |
| PH12016502355B1 (en) | Pharmaceutical composition | |
| NZ734516A (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n’-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| NZ700761A (en) | Salt form of a human histone methyltransferase ezh2 inhibitor | |
| RU2017105353A (ru) | Соединения | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| WO2016109217A3 (en) | Btk inhibitors | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| JP2019529569A5 (ru) | ||
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| MX2016009226A (es) | Combinaciones farmaceuticas. | |
| MX2016010482A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer. | |
| GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
| EA201992816A1 (ru) | Фармацевтическая композиция и лекарственная форма, которая включает (e)-4-(2-(аминометил)-3-фтораллилокси)-n-трет-бутилбензамид, способ их приготовления, способы лечения и их применения | |
| GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Reissue of patent specification | ||
| TK49 | Information related to patent modified |
Free format text: CORRECTION TO CHAPTER -FG4A- IN JOURNAL 35-2020 FOR INID CODE(S) (54) |